

February 7, 2024



Cellecstar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellecstar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and chief executive officer of Cellecstar, will present an overview of the company at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually. Details of the presentation are as follows:

Date: Wednesday, February 14, 2024
Time: 2:00 – 2:30 pm Eastern Time
Webcast: [Click HERE](#)

A replay of the presentation will be available on [Events](#) section of the company's investor relations website.

About Cellecstar Biosciences, Inc.

Cellecstar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.

The company's product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

For more information, please visit www.cellecstar.com and www.wmclinicaltrial.com or join the conversation by liking and following us on the company's social media channels: [Twitter](#), [LinkedIn](#), and [Facebook](#).

Contacts

MEDIA:
Claire LaCagnina
Bliss Bio Health
315-765-1462
clacagnina@blissbiohealth.com

INVESTORS:
Chad Kolean

Chief Financial Officer
investors@collectar.com



Source: Collectar Biosciences